XERS Q4 2022 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+53.0% YoY

Gross Profit

$27M81.0% margin

Operating Income

-$15M-45.8% margin

Net Income

-$13M-39.0% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$345M

Total Liabilities

$299M

Stockholders' Equity

$45M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$22M	+53.0%
Gross Profit	$27M	$17M	+60.0%
Operating Income	-$15M	-$48M	+68.6%
Net Income	-$13M	-$51M	+74.5%

Revenue Segments

Product

$33M70%

Keveyis

$14M30%